Jerad G. Seurer Form 3 AVADEL PHARMACEUTICALS / Jerad G. Seurer ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Seurer Jerad G.

(Last) (First) (Middle)

C/O AVADEL PHARMACEUTICALS PLC

10 EARLSFORT TERRACE

(Street)

DUBLIN 2 L2 D02 T380

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2024

3. Issuer Name and Ticker or Trading Symbol
AVADEL PHARMACEUTICALS PLC [ AVDL ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Gen. Counsel & Corp. Secretary

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	8,795	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	11/07/2027	Ordinary Shares	25,000	9.67	D
Stock Option (Right to Buy)	(1)	01/02/2030	Ordinary Shares	30,000	7.55	D
Stock Option (Right to Buy)	(2)	12/08/2030	Ordinary Shares	80,000	6.79	D
Stock Option (Right to Buy)	(3)	12/07/2031	Ordinary Shares	47,500	8.2	D
Stock Option (Right to Buy)	(4)	08/04/2032	Ordinary Shares	100,000	4.69	D
Stock Option (Right to Buy)	(5)	02/20/2034	Ordinary Shares	125,000	13.57	D

Explanation of Responses:

1. Options fully vested and exercisable.

2. Options become exercisable as to 20,000 ordinary shares on each of the first four anniversaries after the 12/8/2020 grant date.

3. Options become exercisable as to 11,875 ordinary shares on each of the first four anniversaries after the 12/7/2021 grant date.

4. Options become exercisable as to 50,000 ordinary shares on each of 6/1/2023 and 6/1/2024.

5. Options become exercisable as to 31,250 ordinary shares on each of the first four anniversaries after the 2/20/2024 grant date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jerad G. Seurer	05/03/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.